FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia GravisByVictoria JohnsonJanuary 14th 2026
Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus ErythematosusByChelsie DermanJanuary 14th 2026
The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey-Goldman, MDByRosalind Ramsey-Goldman, MDJanuary 13th 2026
Tirzepatide Boosts Izekizumab Efficacy for PsA and Obesity Disease ControlByVictoria JohnsonJanuary 12th 2026